Evaluation of Repeat Administration of Purified Poloxamer 188

PHASE3CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 30, 2016

Conditions
Sickle Cell Disease
Interventions
DRUG

MST-188

Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours.

Trial Locations (9)

33021

Joe Dimaggio Children's Hospital, Hollywood

33908

Children's Hospital of Southwest Florida, Fort Myers

70808

Our Lady of the Lake Children's Hospital, Baton Rouge

Unknown

Rady Children's Hospital, San Diego

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

University of Iowa Children's Hospital, Iowa City

Rutgers University, New Brunswick

Medical University of South Carolina, Charleston

T. C. Thompson Children's Hospital, Chattanooga

Sponsors
All Listed Sponsors
lead

Mast Therapeutics, Inc.

INDUSTRY

NCT02449616 - Evaluation of Repeat Administration of Purified Poloxamer 188 | Biotech Hunter | Biotech Hunter